Evidence map›Paper›PMID 36104199›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Anti-signal Recognition Particle Antibody-positive Immune-mediated Myopathy after mRNA-1273 SARS-CoV-2 Vaccination.

Masanobu Tanemoto, Ryosuke Oda, Yuichiro Toyama, Hirohiko Shizukawa, Kazuki Yokokawa, Taro Saito, Syuuichirou Suzuki, Akihiro Matsumura, Shin Hisahara

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Masanobu TanemotoDepartment of Neurology, Sapporo Medical University School of Medicine, Japan.
Ryosuke OdaDepartment of Neurology, Sapporo Kosei General Hospital, Japan.
Yuichiro ToyamaDepartment of Neurology, Sapporo Kosei General Hospital, Japan.
Hirohiko ShizukawaDepartment of Neurology, Sapporo Kosei General Hospital, Japan.
Kazuki YokokawaDepartment of Neurology, Sapporo Medical University School of Medicine, Japan.
Taro SaitoDepartment of Neurology, Sapporo Medical University School of Medicine, Japan.
Syuuichirou SuzukiDepartment of Neurology, Sapporo Medical University School of Medicine, Japan.
Akihiro MatsumuraDepartment of Neurology, Sapporo Medical University School of Medicine, Japan.
Shin HisaharaDepartment of Neurology, Sapporo Medical University School of Medicine, Japan.
Sapporo Medical University · JPSapporo Kosei General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 26-year-old Japanese woman developed a fever, myalgia and gait disturbance one day after receiving the second dose of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. A neurological examination revealed symmetrical weakness and myalgia in proximal lower limbs, and a blood examination showed prominent elevation of creatinine kinase. Magnetic resonance imaging (MRI) revealed a high signal intensity in the thigh muscles on short-tau inversion recovery images, and antibody testing revealed positive findings for anti-signal recognition particle (SRP) antibody. Thus, anti-SRP antibody-positive immune-mediated myopathy was diagnosed. We initiated immunotherapy, and she was ultimately able to walk stably.

Indexed as

COVID-19Muscular Diseases2019-nCoV Vaccine mRNA-1273AdultAutoantibodiesCOVID-19 VaccinesFemaleHumansMyalgiaSARS-CoV-2Signal Recognition ParticleVaccination2019-nCoV Vaccine mRNA-1273AutoantibodiesCOVID-19 VaccinesSignal Recognition Particleanti-signal recognition particle antibodyimmune-mediated necrotizing myopathymyopathySARS-CoV-2vaccine

Identifiers

PMID36104199
PMCPMC9790798
OpenAlexW4295908221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.